The decline in precancerous cervical lesions is most likely due to HPV vaccination and updated cervical cancer screening recommendations.
Precancerous cervical lesions, known as high-grade cervical lesions (CIN2+) can develop a few years after infection and have been used to monitor human papillomavirus (HPV) vaccine impact since cancers can take decades to develop. Additionally, HPV causes about 30,000 cancers in the United States each year, with cervical cancer being the most common.
The CDC analyzed data from the HPV Impact Monitoring Program (HPV-IMPACT), a population-based CIN2+ surveillance system across 5 locations, to determine rates of CIN2+ among women at least 18 years of age during 2008-2016.
The study found that the CIN2+ rates declined significantly in women 18-24 years of age with the number of cases at 216,000 in 2008 and 196,000 in 2016.
The rates also increased significantly in women 40-64 years of age.
1
The decline in precancerous cervical lesions is most likely due to HPV vaccination and updated cervical cancer screening recommendations, according to the study.
A version of this article was originally published by Pharmacy Times. VisitPharmacyTimes.comto view the full article.